Strengths
- Public sources corroborate $200M seed, $350M Series A and about $550M total raised, with valuation above $1.3B.
- Company pages publicly market Iris, Catalyst and Creation.
- Greenhouse shows active hiring signals across functions and hubs.
Diligence report
Lila Sciences
Lila Sciences Startup Diligence Report
Proceed to confirmatory diligence only. The thesis depends on proving that Lila can convert a well-funded science-factory platform into repeatable, defensible, high-margin commercial outcomes with manageable regulatory, IP, supplier and talent risk.
Company profile
Lila Sciences Startup Diligence Report
Lila Sciences has strong public financing validation and a compelling AI-for-science narrative, but public evidence is insufficient to underwrite product-market fit, revenue quality, unit economics, customer concentration, IP defensibility or legal/regulatory exposure.
- Website
- www.lila.ai
- Sector
- AI-native scientific discovery, autonomous laboratories and life-science/materials R&D platforms
- Geography
- United States with San Francisco and Cambridge, MA signals; United Kingdom hiring footprint; global scientific markets
- Stage
- Private venture-backed growth-stage / unicorn
- Known aliases
- Lila, Lila AI, Lila Sciences, Inc., LILA SCIENCES
- Report version
- 1.0
- Timezone
- UTC
Executive summary
Risks
- Operating financial quality and runway are private.
- Product maturity and AI/lab performance are not independently validated.
- No public top-customer, concentration or retention data was found.
- Competition and compute/lab operating intensity may pressure margins.
Gaps
- Financials, KPI pack, ARR/bookings, gross margin, cash runway and budget-to-actuals.
- Cap table, financing documents, investor rights, debt, side letters and option pool.
- Top customers, contracts, renewals, churn/NRR, concentration and references.
- Product telemetry, pricing, roadmap, reliability, model benchmarks, lab throughput and cost-to-serve.
- Patent schedule, invention assignments, data rights, OSS review, regulatory/legal memo and EHS/insurance records.
Risk register
R-001: Operating financial quality is private
Operating financial quality is private
Diligence request: Run finance diligence on financial statements, KPI pack and runway.
R-003: Product maturity and performance are not independently validated
Product maturity and performance are not independently validated
Diligence request: Request telemetry, benchmarks, incident history and customer references.
R-005: Competitive intensity and science-factory operating costs
Competitive intensity and science-factory operating costs
Diligence request: Benchmark performance, cost-to-serve, supplier contracts and win/loss.
R-004: Customer concentration and revenue quality are unknown
Customer concentration and revenue quality are unknown
Diligence request: Obtain customer ARR, contracts, renewals, churn and references.
R-002: Headline valuation may hide investor-rights complexity
Headline valuation may hide investor-rights complexity
Diligence request: Review financing docs, preferences, debt and option pool.
R-007: IP defensibility is not publicly proven
IP defensibility is not publicly proven
Diligence request: Run patent/FTO, assignment, data-rights and OSS diligence.
R-008: Scaling multidisciplinary AI/lab organization is execution-heavy
Scaling multidisciplinary AI/lab organization is execution-heavy
Diligence request: Review HRIS, org chart, attrition, compensation and key-person risk.
R-006: Regulatory, lab-safety and legal exposure needs counsel review
Regulatory, lab-safety and legal exposure needs counsel review
Diligence request: Counsel review of dockets, EHS, insurance, privacy and product classification.
01Financial Information
Public financing is well supported; operating financial quality, current runway and cap-table economics remain private.
I.A Annual and quarterly financial information for the past three years
not publicly verifiable confidence: high
No audited financials, KPI pack, backlog or AR aging were found publicly.
Evidence gaps
- Need audited financials, KPIs, cash runway, backlog and AR aging.
Hidden risks
- Financial quality could diverge from valuation.
Follow-up questions
- Provide audited financials, KPIs, cash runway, backlog and AR aging.
| item | public signal | verification status | diligence request |
|---|---|---|---|
| ARR / revenue | No public revenue or ARR found | not_publicly_verifiable | Request ARR, bookings and deferred revenue. |
| Gross margin / unit economics | No public compute/lab cost or cost-to-serve data | not_publicly_verifiable | Request COGS, compute/lab spend and margin bridge. |
| Cash runway / burn | Headline $550M total raised; cash and burn undisclosed | partially_verified | Request monthly cash, burn and runway. |
I.B Financial Projections
not publicly verifiable confidence: high
No public projections or scenario assumptions were found.
Evidence gaps
- Need three-year model and board-approved plan.
Hidden risks
- Science-factory capex and compute/lab costs may be high.
Follow-up questions
- Provide three-year model and board-approved plan.
I.C Capital Structure
partially verified confidence: medium
Headline investors and amounts are public; share counts, preferences and debt are not.
Evidence gaps
- Need cap table, financing docs and debt/option schedules.
Hidden risks
- Preference stack or debt could impair economics.
Follow-up questions
- Provide cap table, financing docs and debt/option schedules.
| item | public signal | verification status | diligence request |
|---|---|---|---|
| Flagship Pioneering | Creator/incubator and seed-financing source | partially_verified | Confirm equity, board rights and IP transfer terms. |
| Series A investors | Publicly associated with Series A | verified | Request investor rights, preferences and side letters. |
| Employees / option pool | Active hiring implies equity plan is material | not_publicly_verifiable | Request option pool and grant ledger. |
I.D Other financial information
partially verified confidence: medium
Financing history is partly public; tax and accounting policies are private.
Evidence gaps
- Need tax schedules, accounting policies and financing ledger.
Hidden risks
- Revenue recognition and tax positions cannot be tested publicly.
Follow-up questions
- Provide tax schedules, accounting policies and financing ledger.
| item | public signal | verification status | diligence request |
|---|---|---|---|
| Seed / launch financing | $200M seed described in launch materials | verified | Request primary financing docs. |
| Series A / total raised | $350M Series A; about $550M total raised and valuation reference above $1.3B | verified | Request cap table and preference stack. |
| Debt/notes/warrants | No public schedule found | not_publicly_verifiable | Request all debt, notes and warrants. |
02Products
Lila markets a broad AI-for-science platform and named products, but pricing, production adoption and reliability are undisclosed.
II.A Description of each product
partially verified confidence: medium
Public pages support product messaging around scientific superintelligence, Iris, Catalyst and Creation; commercial performance remains private.
Evidence gaps
- Need roadmap, pricing book, deployments, benchmarks and cost-to-serve.
Hidden risks
- Broad claims could mask pre-commercial or services-heavy deployments.
Follow-up questions
- Provide roadmap, pricing book, deployments, benchmarks and cost-to-serve.
| item | public signal | verification status | diligence request |
|---|---|---|---|
| Scientific Superintelligence / AI Science Factory | Company-level platform narrative | partially_verified | Validate model benchmarks and lab throughput. |
| Iris | Publicly marketed product/solution | verified | Confirm active users, retention and reliability. |
| Catalyst / Creation | Publicly marketed product/solution pages | verified | Validate production deployments and cost-to-serve. |
| item | public signal | verification status | diligence request |
|---|---|---|---|
| Iris / Catalyst / Creation | No public list pricing found | not_publicly_verifiable | Request pricing book, discounts and ARR by SKU. |
| Competitor pricing | Most direct AI-science competitors do not publish simple list prices | partially_verified | Benchmark contracts against direct competitors. |
03Customer Information
Public materials do not identify paying customers or revenue concentration; visible relationships are mainly investors and formation/financing ecosystem.
III.A Top customers by application
not publicly verifiable confidence: high
No top-customer list or application-level revenue schedule was found publicly.
Evidence gaps
- Need top-15 customer schedule by application.
Hidden risks
- A small number of confidential customers could dominate revenue.
Follow-up questions
- Provide top-15 customer schedule by application.
| item | public signal | verification status | diligence request |
|---|---|---|---|
| Named paying customers | None identified in reviewed public sources | not_publicly_verifiable | Request top-15 customer list and references. |
| Target scientific users | Company pages describe audiences, not customer contracts | partially_verified | Confirm active users and paid deployments. |
III.B Strategic relationships
partially verified confidence: medium
Public strategic signals include financing ecosystem relationships, not disclosed commercial partnerships.
Evidence gaps
- Need strategic-partner contracts and revenue contribution.
Hidden risks
- Investor validation may be mistaken for customer validation.
Follow-up questions
- Provide strategic-partner contracts and revenue contribution.
| item | public signal | verification status | diligence request |
|---|---|---|---|
| Flagship Pioneering | Creator/incubator/seed ecosystem | verified | Confirm IP transfer, shared services and equity terms. |
| General Catalyst / Series A syndicate | Financing/investor relationship | verified | Request investor rights and customer-introduction role. |
| Commercial strategic partners | No named paid partnerships identified | not_publicly_verifiable | Request agreements and revenue contribution. |
III.C Revenue by customer
not publicly verifiable confidence: high
Revenue by customer and accounts above 5% of revenue are not public.
Evidence gaps
- Need customer revenue concentration and renewal/churn schedule.
Hidden risks
- Unknown concentration could create renewal and roadmap risk.
Follow-up questions
- Provide customer revenue concentration and renewal/churn schedule.
III.D Significant relationships severed within the last two years
not publicly verifiable confidence: low
No severed relationships were found publicly; private confirmation is required.
Evidence gaps
- Disclose material customer, partner and supplier terminations.
Hidden risks
- Quiet customer or supplier churn may be invisible.
Follow-up questions
- Disclose material customer, partner and supplier terminations.
III.E Top suppliers
not publicly verifiable confidence: medium
Compute, lab automation, data and facility suppliers are likely important but not publicly identified.
Evidence gaps
- Need supplier spend, material contracts and redundancy plans.
Hidden risks
- Single-source cloud/lab/data vendors could constrain delivery.
Follow-up questions
- Provide supplier spend, material contracts and redundancy plans.
| item | public signal | verification status | diligence request |
|---|---|---|---|
| Cloud/GPU compute | Model training/inference likely; vendor not named | not_publicly_verifiable | Request cloud contracts and committed spend. |
| Robotics/lab automation | Implied by science-factory narrative; vendors not named | not_publicly_verifiable | Request vendor list, SLAs and uptime. |
| Scientific datasets / data licenses | Data rights not disclosed | not_publicly_verifiable | Request data inventory and lineage. |
04Competition
Lila competes in a crowded AI-for-science landscape across biology, drug discovery, protein design and materials discovery.
IV.A Competitive landscape by market segment
verified confidence: medium
Public competitor materials show substantial overlap in AI-enabled discovery and lab/data loops.
Evidence gaps
- Need win/loss, benchmarks, customer references and FTO review.
Hidden risks
- Well-funded peers could out-execute broad platform claims.
Follow-up questions
- Provide win/loss, benchmarks, customer references and FTO review.
| item | public signal | verification status | diligence request |
|---|---|---|---|
| Recursion / Insilico / Generate / Xaira | AI-enabled drug/biology discovery overlap | verified | Compare data, lab scale, partnerships and economics. |
| EvolutionaryScale / CuspAI | AI biology/materials adjacency | verified | Compare model access, domain breadth and customer adoption. |
| item | public signal | verification status | diligence request |
|---|---|---|---|
| Proprietary data and feedback loop | Core Lila narrative; competitors also claim data/model advantages | partially_verified | Verify data rights, quality, scale and model uplift. |
| Customer trust and commercial validation | No named customers found | not_publicly_verifiable | Request customer references, renewals and paid deployments. |
| Capital and talent | Strong financing and hiring signals | partially_verified | Test hiring productivity and burn efficiency. |
05Marketing, Sales, and Distribution
Public GTM evidence shows owned messaging, product pages, investor PR and hiring; sales productivity, pipeline and budget are private.
V.A Strategy and implementation
partially verified confidence: medium
Lila positions through an expert-led scientific platform narrative and financing announcements; channel economics are not disclosed.
Evidence gaps
- Need GTM plan, channel pipeline and campaign metrics.
Hidden risks
- Enterprise science sales cycles can be long and proof-of-value intensive.
Follow-up questions
- Provide GTM plan, channel pipeline and campaign metrics.
| item | public signal | verification status | diligence request |
|---|---|---|---|
| Owned website/product pages | Homepage, technology and product pages | verified | Request traffic, conversion and lead quality. |
| Investor/PR network | Financing announcements | verified | Request pipeline attribution. |
| Direct scientific enterprise BD | Inferred from high-complexity product and no public pricing | inconclusive | Request sales team, pipeline and cycle data. |
| item | public signal | verification status | diligence request |
|---|---|---|---|
| Category narrative | Scientific Superintelligence / AI Science Factory language | partially_verified | Needs customer outcome proof. |
| Financing PR | Seed and Series A announcements | verified | Validates capital access, not PMF. |
| Recruiting | Open roles on Greenhouse | verified | Indicates operating activity and hiring needs. |
V.B Major Customers
not publicly verifiable confidence: high
Major-customer status, trends, growth prospects and pipeline are not public.
Evidence gaps
- Need major-customer and pipeline analysis.
Hidden risks
- Pipeline may depend on a few pilots or strategic accounts.
Follow-up questions
- Provide major-customer and pipeline analysis.
V.C Principal avenues for generating new business
inconclusive confidence: medium
Likely avenues include direct scientific BD, founder/investor networks and thought leadership, but actual sourcing mix is private.
Evidence gaps
- Need source-of-pipeline and conversion funnel.
Hidden risks
- Founder/investor-led sourcing may not scale.
Follow-up questions
- Provide source-of-pipeline and conversion funnel.
V.D Sales force productivity model
not publicly verifiable confidence: high
Compensation, quota, sales cycle, attainment and hiring productivity are not public.
Evidence gaps
- Need sales productivity model, comp plan and quotas.
Hidden risks
- Hiring ahead of commercial proof could increase burn.
Follow-up questions
- Provide sales productivity model, comp plan and quotas.
V.E Ability to implement marketing plan with current and projected budgets
not publicly verifiable confidence: medium
Budget adequacy cannot be judged publicly; large financing provides capacity but not efficiency proof.
Evidence gaps
- Need GTM budget and spend-to-pipeline metrics.
Hidden risks
- Capital may fund experimentation without repeatable GTM economics.
Follow-up questions
- Provide GTM budget and spend-to-pipeline metrics.
06Research and Development
R&D is central: public pages describe AI, data and automation loops; datasets, model performance, lab throughput and roadmap economics remain private.
VI.A Description of R&D organization
partially verified confidence: medium
Public hiring and technology pages indicate a multidisciplinary R&D organization spanning AI/software, robotics/automation and domain science.
Evidence gaps
- Need R&D plan, budget, model evaluation and lab throughput metrics.
Hidden risks
- R&D complexity could create technical debt, high capex and slippage.
Follow-up questions
- Provide R&D plan, budget, model evaluation and lab throughput metrics.
| item | public signal | verification status | diligence request |
|---|---|---|---|
| AI/ML and software engineering | Open roles and technology narrative | verified | Review model team size, roadmap and productivity. |
| Robotics/lab automation | Science-factory narrative and relevant hiring signals | partially_verified | Review throughput, uptime and vendor dependencies. |
| Domain science teams | Product pages imply chemistry/materials/life-science expertise | partially_verified | Review bios, publications and retention. |
VI.B New Product Pipeline
partially verified confidence: medium
Iris/Catalyst/Creation are publicly marketed, but stage gates, launch dates, costs and blockers are private.
Evidence gaps
- Need pipeline stage-gate report, technical risk register and IP review.
Hidden risks
- Pipeline could be R&D-heavy without scalable repeatable revenue.
Follow-up questions
- Provide pipeline stage-gate report, technical risk register and IP review.
| item | public signal | verification status | diligence request |
|---|---|---|---|
| Iris / Catalyst / Creation | Publicly marketed products/solutions | partially_verified | Request stage gates, adoption and cost-to-complete. |
| Patent/IP protection | Trademark visible; patent portfolio not verified | inconclusive | Request IP schedule, assignments and FTO review. |
07Management and Personnel
Public hiring and leadership signals support an active scale-up, but management depth, compensation, retention and employee-relations matters require private HR diligence.
VII.A Organization Chart
not publicly verifiable confidence: medium
Only a high-level inferred org can be built from public sources; formal reporting lines are private.
Evidence gaps
- Need official org chart and leadership succession plan.
Hidden risks
- Rapid cross-functional growth can create unclear ownership.
Follow-up questions
- Provide official org chart and leadership succession plan.
Formal reporting lines are illustrative and require company confirmation.
VII.B Historical and projected headcount by function and location
partially verified confidence: medium
Greenhouse indicates hiring in multiple hubs, but historical/projected headcount is not public.
Evidence gaps
- Need headcount by function/location and hiring plan.
Hidden risks
- Hiring plan may outpace management systems or lab capacity.
Follow-up questions
- Provide headcount by function/location and hiring plan.
| item | public signal | verification status | diligence request |
|---|---|---|---|
| San Francisco / Cambridge MA / London | Public job-board hub signals | verified | Request headcount by office and facilities plan. |
| AI/software, robotics, science and operations | Role categories visible on job board | verified | Request hiring funnel, compensation bands and attrition. |
VII.C Senior management biographies
partially verified confidence: medium
Public information identifies limited leadership signals, but comprehensive bios and tenure are private.
Evidence gaps
- Need senior management bios and references.
Hidden risks
- Key-person risk may be concentrated around founding technical leadership.
Follow-up questions
- Provide senior management bios and references.
| item | public signal | verification status | diligence request |
|---|---|---|---|
| Geoffrey von Maltzahn | Founder/CEO-level leadership signal in public materials | partially_verified | Confirm title, tenure, references and outside commitments. |
| AI/science/commercial leadership | Full public roster not verified | not_publicly_verifiable | Request accountable leaders, bios and reporting lines. |
VII.D Compensation arrangements
not publicly verifiable confidence: high
Employment agreements, compensation bands and benefit plans are not public.
Evidence gaps
- Need compensation, benefits and employment agreements.
Hidden risks
- AI/science talent market may require high retention packages.
Follow-up questions
- Provide compensation, benefits and employment agreements.
VII.E Incentive stock plans
not publicly verifiable confidence: high
Option pool, grants, vesting, exercise prices and refresh policies are not public.
Evidence gaps
- Need equity plan and grant ledger.
Hidden risks
- Option pool insufficiency could create dilution or retention pressure.
Follow-up questions
- Provide equity plan and grant ledger.
VII.F Significant employee relations problems, past or present
inconclusive confidence: low
No public employee-relations problems were identified, but public sources are insufficient.
Evidence gaps
- Disclose material complaints, investigations and settlements.
Hidden risks
- Culture, safety and employee-relations matters may not be public.
Follow-up questions
- Disclose material complaints, investigations and settlements.
| item | public signal | verification status | diligence request |
|---|---|---|---|
| Executive departures / layoffs | No obvious material public signals found | inconclusive | Request board minutes, resignation notices and HRIS. |
| Turnover and employee-relations matters | Not public | not_publicly_verifiable | Request two-year turnover and investigations/settlements. |
VII.G Personnel Turnover
not publicly verifiable confidence: high
Turnover and retention metrics are not public.
Evidence gaps
- Need two-year turnover data and retention plan.
Hidden risks
- High technical turnover could impair product delivery and IP continuity.
Follow-up questions
- Provide two-year turnover data and retention plan.
08Legal and Related Matters
Public legal/IP evidence is thin: a trademark application is visible, while patents, material contracts, insurance, enforcement actions and litigation require counsel-led diligence.
VIII.A Pending lawsuits against the Company
inconclusive confidence: low
No obvious material public litigation against Lila was found in limited search; counsel confirmation is required.
Evidence gaps
- Have counsel run federal/state docket searches and disclose claims.
Hidden risks
- Docket coverage, sealed matters and threatened claims may be invisible.
Follow-up questions
- Have counsel run federal/state docket searches and disclose claims.
| item | public signal | verification status | diligence request |
|---|---|---|---|
| Material litigation against Lila | No obvious material case identified in limited public search | inconclusive | Counsel-run federal/state docket search and dispute disclosure. |
| Threatened claims or arbitration | Not public | not_publicly_verifiable | Request counsel memo and management representation. |
Legal timeline omitted to keep standard depth at 12 figures; legal/IP/regulatory items appear in VIII tables and this heatmap.
VIII.B Pending lawsuits initiated by Company
inconclusive confidence: low
No obvious public lawsuits initiated by Lila were identified in limited search.
Evidence gaps
- Disclose all initiated claims and dispute correspondence.
Hidden risks
- IP or contract disputes could exist outside easily searchable records.
Follow-up questions
- Disclose all initiated claims and dispute correspondence.
| item | public signal | verification status | diligence request |
|---|---|---|---|
| Lila as plaintiff | No obvious public matter identified in limited search | inconclusive | Counsel-run docket and demand-letter search. |
| IP/contract enforcement | Not public | not_publicly_verifiable | Disclose enforcement, disputes and settlement agreements. |
VIII.C Environmental and employee safety issues and liabilities
not publicly verifiable confidence: medium
AI science-factory and lab operations make safety and environmental controls important, but facility details are private.
Evidence gaps
- Need EHS policies, permits, incident logs and insurance.
Hidden risks
- Wet-lab, robotics or chemicals work can create compliance liabilities.
Follow-up questions
- Provide EHS policies, permits, incident logs and insurance.
VIII.D Material patents, copyrights, licenses, and trademarks
partially verified confidence: medium
A LILA SCIENCES trademark application is visible; patents, licenses and assignments were not publicly verified.
Evidence gaps
- Need IP schedule, assignments, FTO and OSS/data-license review.
Hidden risks
- Data-license or invention-assignment gaps could weaken defensibility.
Follow-up questions
- Provide IP schedule, assignments, FTO and OSS/data-license review.
| item | public signal | verification status | diligence request |
|---|---|---|---|
| LILA SCIENCES trademark | US trademark serial 99097748 in public mirrors | partially_verified | Confirm current USPTO status, owner, classes and prosecution history. |
| Patent portfolio | No broad Lila patent portfolio verified | inconclusive | Request patent schedule, assignments and FTO files. |
| Trade secrets, datasets, software licenses | Not public | not_publicly_verifiable | Request data rights, invention assignments and OSS scan. |
VIII.E Insurance coverage and material exposures
not publicly verifiable confidence: high
Insurance coverage is not public.
Evidence gaps
- Need insurance schedule and claims history.
Hidden risks
- Lab, cyber, D&O, E&O and product-liability coverage may be inadequate.
Follow-up questions
- Provide insurance schedule and claims history.
VIII.F Material contracts
not publicly verifiable confidence: high
Material customer, supplier, financing, data-license and lab/facility contracts are private.
Evidence gaps
- Need material contracts and data licenses.
Hidden risks
- Exclusivity, data restrictions or change-of-control clauses could constrain the business.
Follow-up questions
- Provide material contracts and data licenses.
VIII.G Regulatory agency problems
inconclusive confidence: medium
No Lila-specific regulatory enforcement action was found publicly; AI/life-science regulatory pathways remain diligence items.
Evidence gaps
- Need regulatory compliance matrix and agency correspondence.
Hidden risks
- Product outputs could trigger FDA, privacy, export-control or lab-safety obligations.
Follow-up questions
- Provide regulatory compliance matrix and agency correspondence.
| item | public signal | verification status | diligence request |
|---|---|---|---|
| FDA / therapeutic AI use cases | No Lila-specific action found; FDA AI/ML context relevant | inconclusive | Review product classification, validation and agency correspondence. |
| Lab safety / environmental | No public Lila-specific enforcement found | not_publicly_verifiable | Review EHS permits, incident logs and insurance. |
| Privacy, export control and data rights | Not assessed in public sources | not_publicly_verifiable | Counsel review for collaborations, models and materials use cases. |
Evidence
| ID | Claim | Status | Sources |
|---|---|---|---|
| EC-001 | Lila launched with a $200M seed financing. | verified medium | SRC-007SRC-010 |
| EC-002 | Lila announced a $350M Series A and about $550M total raised. | verified high | SRC-008SRC-009SRC-007 |
| EC-003 | Round economics, share counts, preferences, debt, tax and cash runway are not public. | not publicly verifiable high | SRC-008SRC-015 |
| EC-004 | Lila publicly positions around Scientific Superintelligence and AI Science Factories. | partially verified medium | SRC-001SRC-002SRC-003 |
| EC-005 | Lila markets Iris, Catalyst and Creation as product/solution areas. | verified medium | SRC-004SRC-005SRC-006 |
| EC-006 | Lila does not publicly disclose pricing or product unit economics. | not publicly verifiable high | SRC-004SRC-005SRC-006 |
| EC-007 | Public research did not identify named paying customers or revenue concentration. | not publicly verifiable high | SRC-001SRC-004SRC-005SRC-006 |
| EC-008 | Visible strategic relationships are mainly financing and formation relationships. | partially verified medium | SRC-008SRC-009SRC-010 |
| EC-009 | Compute, laboratory, robotics and data supplier dependencies are not public. | not publicly verifiable medium | SRC-003SRC-011 |
| EC-010 | AI-for-science competition is crowded across biology, chemistry and materials. | verified medium | SRC-017SRC-018SRC-019SRC-020SRC-021SRC-022 |
| EC-011 | Public GTM signals emphasize owned content, financing PR and hiring, not transparent pricing or channel metrics. | partially verified medium | SRC-001SRC-004SRC-007SRC-011 |
| EC-012 | Greenhouse indicates active hiring across scientific, AI/software and operational functions. | verified medium | SRC-011 |
| EC-013 | Public leadership materials are limited; full org chart, compensation and retention data are private. | partially verified medium | SRC-002SRC-012 |
| EC-014 | Lila R&D claims depend on a closed-loop AI, experimental design, robotics/labs and data feedback system. | partially verified medium | SRC-003SRC-004SRC-005SRC-006 |
| EC-015 | A LILA SCIENCES trademark application with serial 99097748 appears in public trademark mirrors. | partially verified medium | SRC-013SRC-014 |
| EC-016 | No broad public patent portfolio was verified in this review. | inconclusive low | SRC-013SRC-014 |
| EC-017 | No obvious material public litigation was identified, but the search was limited. | inconclusive low | SRC-016 |
| EC-018 | AI-enabled life-science/materials workflows can create regulatory, data, lab-safety and product-liability issues. | partially verified medium | SRC-003SRC-023 |
| EC-019 | Revenue, backlog, AR aging, budget-to-actuals and projections are not public. | not publicly verifiable high | SRC-001SRC-015 |
Disclaimer
This report is a public-evidence diligence snapshot, not investment advice. Important financial, legal, technical, and contractual facts remain non-public and should be verified directly with management and primary documents before any investment decision.